{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Iris+Neoplasms", "query": { "condition": "Iris Neoplasms" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 59, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Iris+Neoplasms&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T05:07:44.198Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01770353", "title": "MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "ER/PR Positive Breast Cancer", "Triple Negative Breast Cancer", "Metastatic Breast Cancer With Active Brain Metastasis" ], "interventions": [ { "name": "Ferumoxytol", "type": "DRUG" }, { "name": "MM-398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2012-11", "completion_date": "2018-10-02", "has_results": true, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-05-22T05:07:44.198Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01770353" }, { "nct_id": "NCT00025181", "title": "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "tyrosinase peptide", "type": "BIOLOGICAL" }, { "name": "adjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 19, "start_date": "2001-10", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-05-22T05:07:44.198Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025181" }, { "nct_id": "NCT02068586", "title": "Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Iris Melanoma", "Stage I Intraocular Melanoma", "Stage IIA Intraocular Melanoma", "Stage IIB Intraocular Melanoma", "Stage IIIA Intraocular Melanoma", "Stage IIIB Intraocular Melanoma", "Stage IIIC Intraocular Melanoma", "Stage I Uveal Melanoma AJCC V7", "Stage II Uveal Melanoma AJCC V7", "Stage III Uveal Melanoma AJCC V7" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Sunitinib Malate + Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2014-11-19", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-05-22T05:07:44.198Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02068586" }, { "nct_id": "NCT05806931", "title": "Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "TAS-102, oxaliplatin, irinotecan with bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-05-17", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-05-22T05:07:44.198Z", "location_count": 9, "location_summary": "Elizabeth, New Jersey • Jersey City, New Jersey • Lakewood, New Jersey + 5 more", "locations": [ { "city": "Elizabeth", "state": "New Jersey" }, { "city": "Jersey City", "state": "New Jersey" }, { "city": "Lakewood", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "Long Branch", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05806931" }, { "nct_id": "NCT01143402", "title": "Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Iris Melanoma", "Medium/Large Size Posterior Uveal Melanoma", "Ocular Melanoma With Extraocular Extension", "Recurrent Uveal Melanoma", "Small Size Posterior Uveal Melanoma", "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2010-06", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-05-22T05:07:44.198Z", "location_count": 32, "location_summary": "Aurora, Colorado • Miami Beach, Florida • Tampa, Florida + 25 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01143402" }, { "nct_id": "NCT07060014", "title": "NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Small Intestine Cancer", "Appendiceal Cancers" ], "interventions": [ { "name": "Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2025-07-18", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-05-22T05:07:44.198Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07060014" }, { "nct_id": "NCT00003802", "title": "Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "pyrazoloacridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-02", "completion_date": "2002-10", "has_results": false, "last_update_posted_date": "2012-12-17", "last_synced_at": "2026-05-22T05:07:44.198Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003802" }, { "nct_id": "NCT00096083", "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "isolated perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 56, "start_date": "2004-09", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2013-10-23", "last_synced_at": "2026-05-22T05:07:44.198Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096083" }, { "nct_id": "NCT00329641", "title": "Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Extraocular Extension Melanoma", "Iris Melanoma", "Metastatic Intraocular Melanoma", "Recurrent Intraocular Melanoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2011-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-07-31", "last_synced_at": "2026-05-22T05:07:44.198Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00329641" }, { "nct_id": "NCT00121225", "title": "Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Extraocular Extension Melanoma", "Iris Melanoma", "Uveal Melanoma", "Recurrent Intraocular Melanoma", "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2005-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2019-01-29", "last_synced_at": "2026-05-22T05:07:44.198Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Rockledge, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Rockledge", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00121225" } ] }